BioCentury | Feb 22, 2016
Clinical News

Toctino alitretinoin: Development discontinued

...GSK discontinued its Toctino U.S. program. Basilea, which granted GSK exclusive, worldwide rights to alitretinoin in...
...Pharmaceutica AG (SIX:BSLN), Basel, Switzerland GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Toctino alitretinoin ( BAL4079...
BioCentury | Dec 21, 2015
Company News

GlaxoSmithKline, Almirall deal

...clindamycin/tretinoin worldwide and Altabax retapamulin in the U.S. in exchange for distribution rights to Toctino alitretinoin...
...Czech Republic, Italy, the Netherlands, Poland, Slovakia, Spain and Mexico. Almirall had distribution rights to Toctino...
...Basilea Pharmaceutica AG (SIX:BSLN, Basel, Switzerland). GSK’s Stiefel Laboratories Inc. subsidiary gained worldwide rights to Toctino...
BioCentury | Jun 18, 2012
Analyst Picks & Changes

Analyst picks & changes

...worldwide rights to its only marketed drug, eczema therapy Toctino alitretinoin (see B6). She said "Toctino...
BioCentury | Jun 18, 2012
Finance

Highlights of weekly biotech stock moves

...CHF44.05 last week after granting Stiefel Laboratories Inc. exclusive, worldwide rights to eczema therapy Toctino alitretinoin...
...could receive low double-digit royalties in the U.S. starting three years after a U.S. launch. Toctino...
BioCentury | Jun 18, 2012
Company News

Basilea, GlaxoSmithKline sales and marketing update

...Inc. subsidiary exclusive, worldwide rights to the Swiss company's only marketed drug, eczema therapy Toctino alitretinoin...
...to Stiefel. Sales of Toctino were CHF31 million ($31 million) in 2011. In the U.S., Toctino...
BioCentury | Jun 12, 2012
Top Story

Basilea out-licenses Toctino to Stiefel

...Laboratories Inc. exclusive, worldwide rights to the Swiss company's only marketed drug, eczema therapy Toctino alitretinoin...
...15 others. Sales of Toctino were CHF31 million ($31 million) in 2011. In the U.S., Toctino...
BioCentury | Apr 2, 2012
Finance

Doubling down

...Xiaflex collagenase clostridium histolyticum Peyronie's disease Ph III data 2Q12 Basilea Pharmaceutica AG (SIX:BSLN) Toctino alitretinoin...
BioCentury | Apr 2, 2012
Finance

Thinking small again

...that group, Kraft likes Switzerland's Basilea Pharmaceutica AG . Last month, its once-daily oral Toctino alitretinoin...
...in a Phase III trial to treat severe chronic hand eczema unresponsive to topical corticosteroids. Toctino...
BioCentury | Mar 19, 2012
Finance

Highlights of weekly biotech stock moves

...week. Basilea Pharmaceutica AG (SIX: BSLN) was up CHF3.30 to CHF50.65 last week after Toctino alitretinoin...
BioCentury | Mar 19, 2012
Clinical News

Toctino alitretinoin: Phase III data

...with severe chronic hand eczema unresponsive to topical corticosteroids showed that once-daily 30 mg oral Toctino...
..."clear" or "almost clear" hands as measured by PGA vs. placebo (40% vs. 15%, p<0.001). Toctino...
...eczema unresponsive to topical corticosteroids. Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Product: Toctino alitretinoin ( BAL4079...
Items per page:
1 - 10 of 137